Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluticasone furoate + fexofenadine is a combination of two pharmaceutical agents used primarily for the treatment of allergic rhinitis and related allergy symptoms. Fluticasone furoate is a synthetic fluorinated corticosteroid that acts as an agonist at the glucocorticoid receptor, exerting potent anti-inflammatory effects in nasal tissues to reduce symptoms such as congestion, sneezing, and runny nose[5][2]. Fexofenadine is a second-generation selective H1-antagonist antihistamine that blocks histamine H1 receptors to alleviate symptoms like itching, sneezing, and watery eyes without causing significant sedation[1][6]. The combination targets both inflammatory and histaminergic pathways involved in allergic responses. Both drugs are available over-the-counter individually; their combination may be used for enhanced symptom control in seasonal or perennial allergic rhinitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluticasone furoate + fexofenadine.